Cancer News and Research

Latest Cancer News and Research

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Keryx Biopharmaceuticals, Inc. today announced that abstract O-0017, entitled "Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC" has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in Barcelona, Spain from June 30 - July 2, 2010.

30 Jun 2010

Asbestos induces cell necrosis, promotes tumor growth

More than 20 million people in the U.S., and many more worldwide, who have been exposed to asbestos are at risk of developing mesothelioma, a malignant cancer of the membranes that cover the lungs and abdomen that is resistant to current therapies.

30 Jun 2010

U.S., China open Shanghai Epidemiology Center for chronic, epidemic diseases

Chinese and U.S. health officials opened an epidemiology center in Shanghai Tuesday to train experts to deal with and prevent chronic and epidemic diseases, the Associated Press reports.

30 Jun 2010

New test to predict DCIS spares unnecessary radiotherapy

A new test could predict which women have an aggressive form of breast cancer in the milk ducts (DCIS) and spare other women from unnecessary radiotherapy, according to research1 published in the British Journal of Cancer today.

30 Jun 2010

USPTO grants Vermillion Alzheimer's disease biomarker patent

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Biomarkers for Alzheimer's disease" to the Company.

29 Jun 2010

Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

Threshold Pharmaceuticals, Inc., today announced that it has initiated a Phase 1 clinical trial of TH-302 in patients with advanced leukemias. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia.

29 Jun 2010

Zymeworks closes $3.2 million financing round

Zymeworks Inc., a privately held biotechnology company focused on the development of next generation antibody-based therapeutics, today announced the close of a financing totaling $3.2 million. The financing consists of a follow-on round of institutional investment by CTI Life Sciences Fund, L.P. ("CTI") which led the Company's previous financing in 2009.

29 Jun 2010

Individual cells react differently to complex signals: Study

Using new technology that allows scientists to monitor how individual cells react in the complex system of cell signaling, Stanford University researchers have uncovered a much larger spectrum of differences between each cell than ever seen before.

29 Jun 2010

New Canadian legislation bans sale of flavoured cigarillos, cigarettes, blunt wraps

Canada's tough new anti-tobacco law, Bill C-32, comes into effect at stores near you on July 5. Retailers will no longer be allowed to sell fruit- and candy-flavoured cigarillos (little cigars), cigarettes, and blunt wraps (rolling papers made of tobacco).

29 Jun 2010

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

Chelsea Therapeutics International, Ltd. announced the initiation of Study 306, a pivotal Phase III trial evaluating the efficacy of NORTHERA™, an oral synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with Parkinson's disease.

29 Jun 2010

Ovarian transplant procedure increases lifespan, restores fertility in aging mice

Scientists have discovered that when they transplant ovaries from young mice into aging female mice, not only does the procedure make the mice fertile again, but also it rejuvenates their behaviour and increases their lifespan. The question now is: could ovarian transplants in women have the same effect?

29 Jun 2010

Mylan Pharmaceuticals receives FDA final approval for Anastrozole Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1 mg, the generic version of AstraZeneca's Arimidex® Tablets, a treatment for early breast cancer.

29 Jun 2010

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.

29 Jun 2010

BIND Biosciences announces $12.4 million Series C-1 financing

BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing best in class therapeutics based on its proprietary targeted nanotechnology platform, announced today that it has secured a $12.4 Million Series C-1 financing. This financing included all of BIND's current investors (including Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension and DHK Investments) as well as a new venture investor, Endeavour Vision, and private investors.

29 Jun 2010

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in the liver and is a pandemic over the globe especially in the developed countries, based on a high calorie diet and sedentary life style. As in the other types of chronic hepatitis, collagen fibers continuously accumulate in the liver through the course of NASH toward cirrhosis and hepatocellular carcinoma development.

29 Jun 2010

AMAG, Takeda provide regulatory and clinical update for Feraheme Injection

AMAG Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited today provided a regulatory and clinical update for Feraheme® (ferumoxytol) Injection for intravenous (IV) use.

29 Jun 2010

AVEO Pharmaceuticals joins Russell 2000 Index and S&P MidCap 400

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company has been added to the Russell 2000® Index, as part of the annual reconstitution of the entire Russell family of indexes that took place on June 25, 2010 following the close of the market.

29 Jun 2010

U.S. Supreme Court declines to hear appeals in civil racketeering lawsuit against cigarette manufacturers

The U.S. Supreme Court today declined to hear appeals in the federal government's civil racketeering lawsuit against cigarette manufacturers. Today's decision upholds the trial court's historic verdict that the cigarette manufacturers are racketeers and have engaged in a decades-long conspiracy to deceive the American public and target children with their deadly and addictive products. That verdict is now final and undeniable: The cigarette manufacturers have been found guilty of engaging in a deadly fraud that is unprecedented in our nation's history.

29 Jun 2010

Tranzyme reports positive results from TZP-102 Phase 2 study in diabetic patients with gastroparesis

Tranzyme Pharma announced positive top-line results today from a Phase 2, double-blind, placebo-controlled study evaluating TZP-102 capsules in diabetic patients with gastroparesis, a serious disorder characterized by the inability of the stomach to empty food efficiently. The study achieved a clinically meaningful and statistically significant improvement in critical gastroparesis-related symptoms. All three TZP-102 doses tested were effective, safe and well tolerated.

29 Jun 2010

Mammalian embryo use different strategies to suppress retroviral infection: Study

Some viruses insert themselves into the host's DNA during infection in a process called retroviral integration, causing several diseases, including AIDS and cancer, notes a Texas A&M researcher who specializes in fetal diseases.

29 Jun 2010

Cancer News and Research

Latest Cancer News and Research

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Asbestos induces cell necrosis, promotes tumor growth

U.S., China open Shanghai Epidemiology Center for chronic, epidemic diseases

New test to predict DCIS spares unnecessary radiotherapy

USPTO grants Vermillion Alzheimer's disease biomarker patent

Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

Zymeworks closes $3.2 million financing round

Individual cells react differently to complex signals: Study

New Canadian legislation bans sale of flavoured cigarillos, cigarettes, blunt wraps

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

Ovarian transplant procedure increases lifespan, restores fertility in aging mice

Mylan Pharmaceuticals receives FDA final approval for Anastrozole Tablets ANDA

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

BIND Biosciences announces $12.4 million Series C-1 financing

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

AMAG, Takeda provide regulatory and clinical update for Feraheme Injection

AVEO Pharmaceuticals joins Russell 2000 Index and S&P MidCap 400

U.S. Supreme Court declines to hear appeals in civil racketeering lawsuit against cigarette manufacturers

Tranzyme reports positive results from TZP-102 Phase 2 study in diabetic patients with gastroparesis

Mammalian embryo use different strategies to suppress retroviral infection: Study

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in